Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Matthew M. Y
Effect of aficamten in obstructive hypertrophic cardiomyopathy with comorbidities: obesity, hypertension, and diabetes: SEQUOIA-HCM substudy
Lee, Matthew M. Y. ORCID: https://orcid.org/0000-0001-9213-2067, Maron, Martin S., Olivotto, Iacopo, Zi Miao, Michael, Lakdawala, Neal K., Fifer, Michael A., Meder, Benjamin, Owens, Anjali T., Jacoby, Daniel L. and Coats, Caroline ORCID: https://orcid.org/0000-0002-3208-470X (2026) Effect of aficamten in obstructive hypertrophic cardiomyopathy with comorbidities: obesity, hypertension, and diabetes: SEQUOIA-HCM substudy.
Multiorgan protective therapy for CKM syndrome: the role of GLP-1-based therapies and SGLT2 inhibitors
Mayne, Kaitlin J., Lee, Matthew M. Y. ORCID: https://orcid.org/0000-0001-9213-2067, Sattar, Naveed ORCID: https://orcid.org/0000-0002-1604-2593 and Herrington, William G. (2026) Multiorgan protective therapy for CKM syndrome: the role of GLP-1-based therapies and SGLT2 inhibitors.
What makes a meta-analysis believable?
Lee, Matthew M Y ORCID: https://orcid.org/0000-0001-9213-2067, Kaul, Sanjay, Krumholz, Harlan M, Pocock, Stuart J, Lam, Carolyn S P and Zannad, Faiez (2026) What makes a meta-analysis believable? Lancet, (doi: 10.1016/S0140-6736(26)01087-1) (PMID:42617619) (Early Online Publication) Full text not currently available from Enlighten. Abstract No abstract available. Articles Early Online Publication Yes Lee, Dr Matthew Lee, M. M. Y., Kaul, S., Krumholz, H. M., Pocock, S. J., Lam, C. S. P., and Zannad, F.
Computer Science > Machine Learning
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website. Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them. Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Do we need exercise echocardiography to diagnose HFpEF? Not at all
Brennan, Alice, Campbell, Ross ORCID: https://orcid.org/0000-0002-0050-2129, Docherty, Kieran F. ORCID: https://orcid.org/0000-0002-5446-9969, Lee, Matthew M. Y. ORCID: https://orcid.org/0000-0001-9213-2067, McMurray, John J. V. ORCID: https://orcid.org/0000-0002-6317-3975, Cleland, John G. F. ORCID: https://orcid.org/0000-0002-1471-7016, Petrie, Mark C.
Heart failure and obesity: novel insights leading to new treatment paradigms
Meems, Laura M. G., van Veldhuisen, Dirk J., Sattar, Naveed ORCID: https://orcid.org/0000-0002-1604-2593 and Lee, Matthew M. Y. ORCID: https://orcid.org/0000-0001-9213-2067 (2025) Heart failure and obesity: novel insights leading to new treatment paradigms. Nature Reviews Cardiology, (doi: 10.1038/s41569-025-01190-7) (PMID:40721643) (Early Online Publication) Full text not currently available from Enlighten.
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
Badve, S. V. et al. (2024) Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes and Endocrinology, (doi: 10.1016/S2213-8587(24)00271-7) (PMID:39608381) (In Press) Text 342922.pdf - Accepted Version Restricted to Repository staff only until 25 May 2025. Available under License Creative Commons Attribution Non-commercial No Derivatives.
Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial
Coats, C. J. et al. (2024) Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. European Heart Journal, (doi: 10.1093/eurheartj/ehae590) (PMID:39217447) (Early Online Publication) Text 337073.pdf - Published Version Available under License Creative Commons Attribution. 1MB Abstract Background and Aims: The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy is not well defined.
Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from from SEQUOIA‐HCM
Coats, C. J. et al. (2024) Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from from SEQUOIA‐HCM. Journal of the American Heart Association, 13(5), e035993. (doi: 10.1161/JAHA.124.035993) (PMID:39056349) Text 337074.pdf - Published Version Available under License Creative Commons Attribution.
Heart failure with preserved ejection fraction: Everything the clinician needs to know
Campbell, P., Rutten, F. H., Lee, M. M. Y. , Hawkins, N. M. and Petrie, M. C. (2024) Heart failure with preserved ejection fraction: Everything the clinician needs to know. Lancet, (doi: 10.1016/S0140-6736(23)02756-3) (PMID:38367642) (Early Online Publication) Text 311237.pdf - Accepted Version Restricted to Repository staff only until 14 August 2024. Available under License Creative Commons Attribution Non-commercial No Derivatives.
Advances in Multi-Modality Imaging in Hypertrophic Cardiomyopathy
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Appetite and its regulation: are there palatable interventions for heart failure?
Lee, M. M. Y. , Lean, M. E. J. , Sattar, N. and Petrie, M. C. (2023) Appetite and its regulation: are there palatable interventions for heart failure? Current Heart Failure Reports, (Accepted for Publication) Text 309761.pdf - Accepted Version Restricted to Repository staff only 174kB Item Type: Articles Status: Accepted for Publication Refereed: Yes Glasgow Author(s) Enlighten ID: Lee, Matthew and Lean, Professor Michael and Sattar, Professor Naveed and Petrie, Professor Mark Authors: Lee, M. M.
Differentiating cardiac troponin levels during cardiac myosin inhibition or cardiac myosin activation treatments: drug effect or the canary in the coal mine?
Lee, M. M. Y. and Masri, A. (2023) Differentiating cardiac troponin levels during cardiac myosin inhibition or cardiac myosin activation treatments: drug effect or the canary in the coal mine? Current Heart Failure Reports, (doi: 10.1007/s11897-023-00620-2) (PMID:37875744) (Early Online Publication) Text 304279.pdf - Published Version Available under License Creative Commons Attribution.
Lack of benefit of renin-angiotensin system inhibitors in COVID-19
Lee, M. M. Y. and McMurray, J. J. V. (2023) Lack of benefit of renin-angiotensin system inhibitors in COVID-19. JAMA: Journal of the American Medical Association, 329(14), pp. 1155-1156. (doi: 10.1001/jama.2023.4405) (PMID:37039803) Text 296872.pdf - Accepted Version 179kB Abstract No abstract available. Item Type: Articles (Editorial) Status: Published Refereed: Yes Glasgow Author(s) Enlighten ID: Lee, Matthew and McMurray, Professor John Authors: Lee, M. M. Y., and McMurray, J. J. V.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Matthew M.
Contact Matthew M., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack